Chemify, a company pioneering the fusion of chemistry, robotics, computation, and artificial intelligence, announced it has raised more than $50 million in an oversubscribed Series B funding round. The financing was co-led by Wing Venture Capital and Insight Partners, with participation from 8VC, Triatomic Capital, Blueyard, Rockspring, and Eos.
The funding will be used to expand Chemify’s Chemputation platform and its global network of Chemifarm facilities, which aim to redefine how molecules are designed, discovered, and manufactured.
Founded in 2022 as a spin-out from the University of Glasgow, Chemify has set out to become the world’s digital backbone of chemistry. The company’s goal is to build a global system for programmable molecular design, enabling on-demand creation of medicines, catalysts, and materials through digitized chemistry. Its Chemputation platform combines a proprietary programming language, advanced robotics, and a vast curated library of validated reactions, offering a new paradigm in molecular discovery and synthesis.
Earlier in 2025, Chemify launched its first Chemifarm in Glasgow, Scotland — a fully automated chemistry facility recognized as one of the most advanced laboratories for molecular design and synthesis in the world. The facility integrates Chemify’s Chemputation technology to convert digital molecular blueprints into physical compounds, dramatically reducing the time from concept to synthesis. The new funding will allow the company to replicate this model worldwide, establishing a network of digital chemistry hubs to support pharmaceutical, biotechnology, and materials science partners.
Chemify also announced plans to open a Silicon Valley facility led by Chief Technical Officer Mike Bell. This U.S. expansion will strengthen Chemify’s presence across the Atlantic and help the company deliver rapid molecular design and synthesis services to a growing global customer base. The expansion marks a major milestone in Chemify’s mission to accelerate the discovery of life-changing medicines and advanced materials while setting a new global standard for digital chemistry.
The company’s vision centers on transforming chemical synthesis from an artisanal process into a precise, programmable science. Through its Chemputation platform, Chemify empowers scientists to automate experimentation, ensure molecule makeability, and unlock new chemical spaces previously out of reach. The Series B funding and new board appointments signal strong investor confidence in Chemify’s approach and technological leadership in digitizing molecular creation.
KEY QUOTES:
“Chemify aims to become the global digital backbone of chemistry, enabling fast design and discovery. Our vision is that Chemify will be able to design and make any molecule on demand for our customers across all of chemistry from drug discovery to new catalysts and electronic materials. The next step in our evolution is nothing short of a revolution in the digitization and automation of chemical discovery and manufacturing.”
Lee Cronin, CEO and Founder, Chemify
“Chemify’s technology uses automation and physical AI to enable the digitization of chemistry, transforming chemical synthesis from an art to a programmable science. We are excited to support the team’s progress as they empower scientists to create novel molecules with unmatched efficiency and precision. Their work has the potential to drive significant advancements in drug discovery and medicine.”
Ansuman Satpathy, Partner, Wing Venture Capital
“Lee is an iconoclast with the wind at his back. Chemify’s use of AI to ensure the makeability of complex molecules is a paradigm shift for how medicinal chemistry is done today, and the company’s vision is matched by the strong results seen across their early pharma collaborations.”
Aiden Aceves, Vice President, Insight Partners
